Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low vs Standard Dose Lopinavir/Ritonavir in HIV-Infected Children
NCT00887120Phase 2Completed
- Sponsor
- HIV-NAT
- Start
- Apr 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by HIV-NAT. Primary endpoint: Pharmacokinetics of standard vs low dose LPV/r at 4 weeks. Started Apr 2007; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00887120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887120.